Research groups
Colleges
DPhil projects available
AKR1C1 as a therapeutic target in non-alcholoic fatty liver diease and hepatocellular carcinoma
Jeremy Tomlinson
MB BCh, PhD, FRCP
Professor of Metabolic Endocrinology
My work tries to better understand and treat metabolic diseases, in particular, non-alcholic fatty liver disease (NAFLD). Our work has focused on the role of steroid hormones and their metabolism in the development, assessment and treatment of metabolic diseases including NAFLD, obesity and type 2 diabetes. Our previous work has shown that altering steroid hormone metabolism can have a potent impact on the function of both liver and adipose tissue to store fat. Our future work will use steroid biomarkers not only to stage disease severity, but to predict progression. In addition, by altering tissue specific-metabolism, we hope to limit the side effects of prescribed steroids.
Key publications
-
Dual-5α-Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man.
Journal article
Hazlehurst JM. et al, (2016), J Clin Endocrinol Metab, 101, 103 - 113
-
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.
Journal article
Armstrong MJ. et al, (2016), J Hepatol, 64, 399 - 408
-
5α-Reductase Type 2 Regulates Glucocorticoid Action and Metabolic Phenotype in Human Hepatocytes.
Journal article
Nasiri M. et al, (2015), Endocrinology, 156, 2863 - 2871
Recent publications
-
Guidelines for the management of glucocorticoids during the peri-operative period for patients with adrenal insufficiency: Guidelines from the Association of Anaesthetists, the Royal College of Physicians and the Society for Endocrinology UK.
Journal article
Woodcock T. et al, (2020), Anaesthesia
-
Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management.
Journal article
Marjot T. et al, (2020), Endocr Rev, 41
-
Plasma Renin Measurements are Unrelated to Mineralocorticoid Replacement Dose in Patients With Primary Adrenal Insufficiency.
Journal article
Pofi R. et al, (2020), J Clin Endocrinol Metab, 105
-
AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease.
Journal article
Nikolaou N. et al, (2019), Metabolism
-
Increased central adiposity and decreased subcutaneous adipose tissue 11β-hydroxysteroid dehydrogenase type 1 are associated with deterioration in glucose tolerance-A longitudinal cohort study.
Journal article
Crowley RK. et al, (2019), Clin Endocrinol (Oxf), 91, 72 - 81